For example, the FASCINATE-1 phase IIb clinical trial (NCT04906421) is investigating TVB-2640, an oral fatty acid synthase (FASN) inhibitor, to assess its safety and efficacy in patients with MASH. This evidence concerns the gene FASN and metabolic dysfunction-associated steatohepatitis.